For a patient with end-stage renal disease, the gap between a matched donor kidney and a successful transplant is measured in hours. Cold storage on ice, the workhorse method for decades, gives surgeons a narrow window before ischemic injury starts to compromise the graft. BMI OrganBank, a seed-stage medical device company in Winston-Salem, North Carolina, is trying to widen that window. The company has secured FDA Breakthrough Device Designation for a portable kidney preservation device co-developed with transplant surgeons, and is preparing to begin clinical studies [BMI OrganBank].
The patient population here is significant and underserved. More than 90,000 Americans sit on the kidney transplant waitlist at any given time, and a meaningful share of recovered organs are never transplanted, often because logistics and preservation windows do not line up with a viable recipient. The standard of care today remains static cold storage: the donor kidney is flushed with preservation solution, packed in ice in an insulated container, and shipped. Hypothermic machine perfusion, in which a pump continuously circulates cold solution through the organ, is increasingly used for higher-risk kidneys and has clinical evidence supporting reduced delayed graft function, but adoption is uneven and the devices are not universally portable. Normothermic and sub-normothermic perfusion approaches are an active area of research and commercial development, with several companies working on liver, heart, and lung systems already in clinical use abroad.
The bet
BMI OrganBank is building a portfolio of perfusion-based devices rather than a single product. Its flagship is the OrganBank Transport device, co-developed with Duke University's DEVOL lab and described by the company as set to launch soon [BMI OrganBank]. A separate portable OrganBank kidney device, co-developed with transplant surgeons, is the program that received FDA Breakthrough Device Designation and is positioned to begin clinical studies [BMI OrganBank]. The underlying perfusion technology is licensed from the Duke Ex-Vivo Organ Lab, led by Drs. Andrew S. Barbas and Matthew Hartwig in the Department of Surgery [BMI OrganBank]. The proprietary OrganBank organ preservation system is currently moving through the FDA clearance process [BMI OrganBank].
The customer in this market is not the patient directly but the organ procurement organization (OPO) and the transplant center. Both are under sustained pressure to reduce discard rates and to expand the geographic radius of viable matches. A device that demonstrably preserves a kidney longer, or in better physiological condition, has a relatively clear value proposition to that buyer: more transplants per recovered organ, better short-term graft function, and fewer logistics-driven losses.
Why it could matter
The regulatory tailwind is real. Breakthrough Device Designation does not guarantee clearance, but it does give the company more frequent FDA interaction and the potential for prioritized review, both of which compress timelines for a small team. The category itself has institutional momentum: federal scrutiny of OPO performance has intensified in recent years, and the transplant community is actively looking for tools that increase organ utilization rather than incremental drugs that improve post-transplant outcomes.
BMI OrganBank's funding profile is modest relative to the ambition. Public records describe a $600,000 seed round and a $3.5 million grant, with the National Institutes of Health among the named backers [Crunchbase]. The company has also been selected by the North Carolina Biotechnology Center for funding to advance its medical device work [BMI OrganBank].
NIH-associated grant | 3.5 | $M
Seed round | 0.6 | $M
Non-dilutive funding is a sensible match for a device company at this stage: it extends runway through preclinical and early clinical work without forcing a premature valuation conversation, and NIH support is a credentialing signal to later-stage strategic and venture investors who will eventually have to underwrite a pivotal study.
The team
Co-founder and CEO Carrie DiMarzio led the development and FDA Emergency Use Authorization of the SuppleVent ventilator during the COVID-19 pandemic, and is now steering the OrganBank system through FDA clearance [BMI OrganBank]. Co-founder George Barr brings more than four decades of work in advanced medical technologies [BMI OrganBank]. Robert Neusner serves as President and COO, with Josh Copus, PhD, and Tyler Adcock among the broader team [BMI OrganBank]. The company also recently announced a strategic partnership with Dedicated Staffing Solutions intended to align its preservation technology with clinical staffing capacity [PR Newswire].
What bears say, and what bulls answer
The most credible concern is execution risk. The kidney device has Breakthrough Designation but has not yet completed the clinical studies that would support a marketing authorization, and the broader perfusion category includes well-capitalized players with multi-organ platforms already deployed in transplant centers. Skeptics will note that the path from a Duke-licensed technology and a designation letter to a commercially adopted device is long, capital-intensive, and historically unforgiving for seed-stage entrants. The bull answer is structural: kidney is the highest-volume solid organ transplant and the one where logistics most often defeat a usable graft, the device has academic surgical co-development baked in from the start through the Duke collaboration [BMI OrganBank], and the regulatory designation should compress the FDA timeline if early clinical data hold.
What to watch
The next twelve months should clarify a great deal. The two milestones that matter most are the start of clinical studies for the portable kidney device and the trajectory of the FDA clearance process for the OrganBank preservation system, both of which the company has publicly committed to [BMI OrganBank]. A priced Series A, the first named OPO or transplant center customer, and any peer-reviewed preclinical data from the Duke collaboration would each meaningfully de-risk the story.
Pulse Raman, Health and Bio Correspondent, Startuply